Vaxcyte saw the highest growth of 1.99% in patent filings in April and 0.99% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Vaxcyte‘s patent filings and grants. Buy the databook here.
Vaxcyte has been focused on protecting inventions in United States(US) with three publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 50% filings and 100% grants. The United States(US), and South Korea(KR) patent Office are among the top ten patent offices where Vaxcyte is filings its patents. Among the top granted patent authorities, Vaxcyte has 100% of its grants in United States(US).
Roche and GSK could be the strongest competitors for Vaxcyte
Inflammation related patents lead Vaxcyte portfolio followed by periodontal disease, and periodontitis
Vaxcyte has highest number of patents in inflammation followed by periodontal disease, periodontitis, osteopenia, and pneumonia.
For comprehensive analysis of Vaxcyte's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.